Tebipenem

立即咨询

Tebipenem

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

161715-21-5

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
50mg	电议

产品介绍

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	383.49
Cas No.	161715-21-5
Formula	C₁₆H₂₁N₃O₄S₂
Solubility	insoluble in EtOH; ≥19.15 mg/mL in H2O with gentle warming; ≥24.9 mg/mL in DMSO
Chemical Name	(4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
Canonical SMILES	CC1C2C(C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)C(C)O
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Tebipenem is an orally available carbapenem antibiotic. Tebipenem is active against a panel of clinical isolates from a variety of bacterial species (MIC50s ≤ 0.0039 ~ 8 μg/ml), including methicillin-resistant strains ofStaphylococcus aureus(S. aureus) andStaphylococcus epidermidis(S. epidermidis), as well as penicillin-resistantStreptococcus pneumoniae(S. pneumonia). Tebipenem also inhibits β-lactamase in a time- and concentration-dependent manner. Tebipenem pivoxil, a derivative of tebipenem, has been under development as the first orally available carbapenem antibiotic for the treatment of respiratory and otolaryngological infections caused by drug-resistantS. pneumoniain pediatric patients.

References:

1. Hazra S, Xu H, Blanchard JS. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry, 2014, 53(22): 3671-3678.

2. Fujimoto K, Takemoto K, Hatano K, et al. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. Antimicrobial Agents and Chemotherapy, 2013, 57(2): 697-707.

试验操作

Animal experiment:[2]
Animal models	A mouse model of penicillin-resistant S. pneumoniae infection
Dosage form	0.32 ~ 3.2 mg/kg Administered intravenously thrice daily 1 day and 2 days after infection
Applications	Tebipenem dose-dependently decreased the number of colony forming units (CFUs) in the lungs of infected mice.
Note	The technical data provided above is for reference only.
	References: 1. Hazra S, Xu H, Blanchard JS. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry, 2014, 53(22): 3671-3678. 2. Fujimoto K, Takemoto K, Hatano K, et al. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. Antimicrobial Agents and Chemotherapy, 2013, 57(2): 697-707.